Cover Image

Vi-TT-a typhoid conjugate vaccine for infants and young children

Saved in:

Bibliographic Details
Main Authors:	Thomas F Wierzba (Author), Avinash K Shetty (Author)
Format:	Book
Published:	Elsevier, 2021-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT).
by: Eun Young Lee, et al.
Published: (2020)

Typhoid conjugate vaccines: making vaccine history in Africa
by: James E. Meiring, et al.
Published: (2018)

Opinion of Parents Regarding Conjugate Typhoid Vaccine
by: M.Hanif Memon, et al.
Published: (2020)

Anti-S. typhi Vi IgG levels in children with and without typhoid vaccinations
by: Sriandayani Sriandayani, et al.
Published: (2014)

The impact of meningococcal conjugate vaccine (MenACWY-TT) on meningococcal carriage in Hajj Pilgrims returning to Turkey
by: Hasan Tezer, et al.
Published: (2020)

A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions
by: Vittal Mogasale, et al.
Published: (2017)

A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report
by: Bernie Endyarni Medise, et al.
Published: (2020)

Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China
by: Yang H.H, et al.
Published: (2001)

Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8-9 months-old Indian children
by: Krishna Mohan Vadrevu, et al.
Published: (2022)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion
by: Silvia Ricci, et al.
Published: (2023)

A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal
by: Shipra Chaudhary, et al.
Published: (2023)

High-resolution genotyping of the endemic Salmonella Typhi population during a Vi (typhoid) vaccination trial in Kolkata.
by: Kathryn E Holt, et al.
Published: (2012)

Delivery cost of the first public sector introduction of typhoid conjugate vaccine in Navi Mumbai, India
by: Dayoung Song, et al.
Published: (2023)

Delivery cost of the first public sector introduction of typhoid conjugate vaccine in Navi Mumbai, India.
by: Dayoung Song, et al.
Published: (2023)

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial
by: Mila Shakya, MPH, et al.
Published: (2021)

Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers
by: Dipesh Tamrakar, et al.
Published: (2024)

Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age
by: Corwin A. Robertson, et al.
Published: (2024)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
by: Timo Vesikari, et al.
Published: (2020)

Single and two-dose typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian children
by: Nginache Nampota-Nkomba, et al.
Published: (2024)

Research priorities to support typhoid conjugate vaccine decision-making in India: evidence assessment and stakeholder survey
by: Andrew Clark, et al.
Published: (2024)

Comparison of safety and immunogenicity of a Vi polysaccharide typhoid vaccine with a whole-cell killed vaccine in Malaysian Air Force recruits
by: Panchanathan Vijayaretnam, et al.
Published: (2001)

Antibodies to the Vi capsule of Salmonella Typhi in the serum of typhoid patients and healthy control subjects from a typhoid endemic region
by: Deborah House1,2, Vo A. Ho4,To S. Diep5, Nguyen T. Chinh6, Phan V. Bay4, Ha Vinh5, Minh Duc4, Christopher M. Parry2,3, Gordon Dougan1, Nicholas J. White2,3, Jeremy J. Farrar2,3, Tran Tinh Hien5, John Wain2,3
Published: (2008)

Public engagement during a typhoid conjugate vaccine trial in Lalitpur, Nepal- experience, challenges and lessons learnt
by: Ashata Dahal, et al.
Published: (2022)

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
by: Gary S. Marshall, et al.
Published: (2022)

A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator
by: Subhash Thuluva, et al.
Published: (2022)

Knowledge, attitudes, and practices of the general population of Pakistan regarding typhoid conjugate vaccine: findings of a cross-sectional study
by: Muhammad Junaid Tahir, et al.
Published: (2023)

A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; Expanding the use of Vi polysaccharide vaccine in Southeast China: A cluster-randomized trial
by: Yang Hong-hui, et al.
Published: (2005)

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study
by: Corwin A. Robertson, et al.
Published: (2023)

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study
by: Germán Áñez, et al.
Published: (2020)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study
by: Judith Kirstein, et al.
Published: (2020)

Typhoid in Africa and vaccine deployment
by: Gordon Dougan
Published: (2017)

Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study
by: J. M. Kemmeren, et al.
Published: (2021)

A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age
by: Josefina Cadorna Carlos, et al.
Published: (2022)

A bright future in typhoid vaccines
by: The Lancet Global Health
Published: (2021)

Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12-23 months in China
by: Jialei Hu, et al.
Published: (2019)

COT-TT vaccine attenuates cocaine-seeking and cocaine-conditioned place preference in rats
by: Susana Barbosa-Méndez, et al.
Published: (2024)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
by: Markus Knuf, et al.
Published: (2022)

Typhoid vaccine: A case for inclusion in national program
by: Pragya Sharma, et al.
Published: (2011)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016)

The Mandate and Supplication of Typhoid Vaccine in Pakistan
by: Aamir Hussain
Published: (2021)